Sarcoidosis Vasculitis And Diffuse Lung Diseases

HO-1 PROTECTS SMOKERS EXPOSED TO ARTIFICIAL STONE DUST FOR PULMONARY FUNCTION TESTS DETERIORATION

HIGH MOBILITY GROUP BOX 1 PROTEIN IN BRONCHOALVEOLAR LAVAGE FLUID AND CORRELATION WITH OTHER INFLAMMATORY MARKERS IN PULMONARY DISEASES

PROCEEDINGS OF THE AMERICAS ASSOCIATION OF SARCOIDOSIS AND OTHER GRANULOMATOUS DISEASES (AASOG) 2017 ANNUAL MEETING

EFFECT OF PULMONARY REHABILITATION ON FUNCTIONAL EXERCISE CAPACITY AND HYPOXEMIA IN PATIENTS WITH INTERSTITIAL LUNG DISEASES: A RETROSPECTIVE STUDY

A 12-WEEK COMBINATION OF CLARITHROMYCIN AND PREDNISONE COMPARED TO A 24-WEEK PREDNISONE ALONE TREATMENT IN CRYPTOGENIC AND RADIATION-INDUCED ORGANIZING PNEUMONIA

CHARACTERIZATION OF LYMPHANGIOLEIOMYOMATOSIS PATIENTS WITH DISCORDANCE BETWEEN SPIROMETRIC AND DIFFUSION MEASUREMENTS OF PULMONARY FUNCTION

RISK OF GASTROINTESTINAL EVENTS AMONG PATIENTS WITH SARCOIDOSIS: A POPULATION-BASED STUDY 1976-2013

SARCOIDOSIS OF THE EXTERNAL NOSE: THE ROLE OF PHARMACOLOGIC RHINOPLASTY IN DIAGNOSIS AND TREATMENT

CIRCULATORY TGF-beta 1 IS SIGNIFICANTLY HIGHER IN EARLY STAGE OF PULMONARY SARCOIDOSIS

AIRWAY-CENTERED INTERSTITIAL FIBROSIS - AN UNDER-RECOGNIZED SUBTYPE OF DIFFUSE PARENCHYMAL LUNG DISEASES